Compare BRID & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRID | EDSA |
|---|---|---|
| Founded | 1932 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.6M | 51.5M |
| IPO Year | 1995 | 2018 |
| Metric | BRID | EDSA |
|---|---|---|
| Price | $5.69 | $3.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.33 |
| AVG Volume (30 Days) | 3.1K | ★ 34.3K |
| Earning Date | 08-24-2026 | 08-13-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $174,257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $5.34 | $0.72 |
| 52 Week High | $8.62 | $20.32 |
| Indicator | BRID | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 35.95 |
| Support Level | $5.65 | $3.47 |
| Resistance Level | $6.23 | $4.27 |
| Average True Range (ATR) | 0.17 | 0.29 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 45.10 | 3.75 |
Bridgford Foods Corp manufactures, markets, and distributes frozen and snack food products in the United States. The two business segments are: the processing and distribution of frozen products, and the processing and distribution of snack food products. Its product offerings include meat snacks, breads and rolls, biscuits, and ready-to-eat sandwiches, among others. The company offers frozen food products to the foodservice and retail customers through wholesalers, cooperatives, and distributors; and snack food items to supermarkets, mass merchandise, and convenience retail stores through customer-owned distribution centers, as well as a direct store delivery network. A majority of the company's revenue is derived from the snack food products segment.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.